Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lona Gaugler"'
Autor:
Amer M. Zeidan, Daniel A. Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Publikováno v:
Annals of Hematology. 102:749-754
Autor:
Reinhard Stauder, Jérémy Lambert, Sandra Desruol‐Allardin, Isabelle Savre, Lona Gaugler, Igor Stojkov, Uwe Siebert, Hélène Chevrou‐Séverac
Publikováno v:
European Journal of Haematology. 104
Autor:
Reinhard Stauder, Igor Stojkov, Jérémy Lambert, Sandra Desruol‐Allardin, Uwe Siebert, Hélène Chevrou‐Séverac, Lona Gaugler, Isabelle Savre
Publikováno v:
European Journal of Haematology
Objectives This study aims to describe the use of patient‐reported outcome measures (PROMs) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) studies and the PROMs landscape. Methods A comprehensive literature review was performed
Autor:
Daniel A. Pollyea, Alberto Vasconcelos, Ravi Potluri, Lona Gaugler, David Rotter, Zephirin Kiendrebeogo, Gaetano Bonifacio, Clara Chen, Uma Borate, Amer M. Zeidan
Publikováno v:
Blood. 138:277-277
INTRODUCTION : Many patients (pts) with newly diagnosed (ND) AML achieve remission with IC regimens, typically comprising cytarabine and an anthracycline, with the eventual goal of therapy being cure. On 21 Nov 2018, the FDA approved venetoclax (VEN)
Autor:
Alberto Vasconcelos, Heather L. Cameron, Beatrice Suero, Clara Chen, Lona Gaugler, C.L. Beach, Gerwin Huls
Publikováno v:
Blood. 138:3015-3015
INTRODUCTION: Oral-AZA was approved in the United States in September 2020 for continued treatment (Tx) of adult patients (pts) with AML in first remission after intensive chemotherapy (IC). The phase 3 QUAZAR AML-001 trial showed that Oral-AZA signi
Autor:
Jürgen Bauer, Boris C. Bastian, Lona Gaugler, Catherine D. Van Raamsdonk, Elizabeth M. Simpson, Gary G. R. Green, Gregory S. Barsh, Joan M. O'Brien, Vladimir Bezrookove
Publikováno v:
Nature, vol 457, iss 7229
Nature
Nature
BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00252248c3b611f8f3a25734b626cf76
https://escholarship.org/uc/item/7k39h80d
https://escholarship.org/uc/item/7k39h80d